미국 · 보도자료 · Cadrenal Therapeutics Inc. · 2026-10-07 11:00
희귀 혈전·염증 치료제 가치 극대화 위한 전략적 검토 절차 착수
PONTE VEDRA, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) (“Cadrenal” or the “Company”), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today announced that its Board of Directors has initiated a formal strategic process to evaluate opportunities to maximize the value of the Company and i
Cadrenal Therapeutics Inc. 다른 공시·급등 이유 보기 · GK의 공시레이더 — 미국·한국 실시간 공시
